Polyethyleneimine is a potent mucosal adjuvant for glycoproteins with innate and adaptive immune activating properties

[1]  C. Coban,et al.  DNA released from dying host cells mediates aluminum adjuvant activity , 2011, Nature Medicine.

[2]  Wolfgang Kreyling,et al.  Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  B. Lambrecht,et al.  Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Mario Cortese,et al.  Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. , 2011, Vaccine.

[5]  J. Dou,et al.  An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. , 2011, Vaccine.

[6]  W. Guo,et al.  Improved antigen cross-presentation by polyethyleneimine-based nanoparticles , 2011, International journal of nanomedicine.

[7]  John Steel,et al.  Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.

[8]  Kang Chen,et al.  Vaccination Strategies to Promote Mucosal Antibody Responses , 2010, Immunity.

[9]  Q. Sattentau,et al.  Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. , 2010, Journal of molecular biology.

[10]  H. Schønheyder,et al.  Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Ya-Wun Yang,et al.  Delivery of DNA-based cancer vaccine with polyethylenimine. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Dan R. Littman,et al.  Th17 and Regulatory T Cells in Mediating and Restraining Inflammation , 2010, Cell.

[13]  R. Rappuoli,et al.  Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.

[14]  B. Pulendran,et al.  Modulation of adaptive immunity with Toll-like receptors. , 2009, Seminars in immunology.

[15]  E. De Gregorio,et al.  Immunology of TLR-independent vaccine adjuvants. , 2009, Current opinion in immunology.

[16]  A. Harandi,et al.  The Mucosal Adjuvant Effect of α-Galactosylceramide for Induction of Protective Immunity to Sexually Transmitted Viral Infection1 , 2009, The Journal of Immunology.

[17]  J. Pounds,et al.  Syndecan-1 mediates the coupling of positively charged submicrometer amorphous silica particles with actin filaments across the alveolar epithelial cell membrane. , 2009, Toxicology and applied pharmacology.

[18]  Jun Chang,et al.  Intranasal Delivery of Cholera Toxin Induces Th17-Dominated T-Cell Response to Bystander Antigens , 2009, PloS one.

[19]  H. Hammad,et al.  Mechanism of action of clinically approved adjuvants. , 2009, Current opinion in immunology.

[20]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[21]  Richard A. Flavell,et al.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.

[22]  B. Beutler,et al.  Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling , 2006, Science.

[23]  A. C. Hunter.  Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. , 2006, Advanced drug delivery reviews.

[24]  F. Maquart,et al.  Cell surface proteoglycan expression during maturation of human monocytes‐derived dendritic cells and macrophages , 2006, Clinical and experimental immunology.

[25]  A. Göpferich,et al.  Polyethylenimine-based non-viral gene delivery systems. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  J. Rosenecker,et al.  Methodological optimization of polyethylenimine (PEI)‐based gene delivery to the lungs of mice via aerosol application , 2005, The journal of gene medicine.

[27]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[28]  S. Akira,et al.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.

[29]  J. Mcghee,et al.  A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. , 2002, Vaccine.

[30]  M. Noda,et al.  A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.